Search the GHTC website

Global health R&D delivers for Idaho

US government investment in global health R&D has delivered

$4.6 million
to Idaho research institutions
Idaho's top USG-funded global health R&D institutions

Idaho's top USG-funded global health R&D institutions

University of Idaho
$3.6 million
Idaho Veterans Research and Education Foundation
$622 thousand
Idaho State University
$440 thousand

Idaho's top areas of global health R&D by USG funding

Bacterial pneumonia & meningitis
Global health R&D at work in Idaho

Researchers from the University of Idaho (U of I) are advancing a novel approach to block the transmission of malaria by “starving” the parasite that causes it. By first creating and then studying a genetically modified strain of mosquito resistant to the parasite, U of I scientists were able to pinpoint the specific biological process responsible for this resistance. They then identified an existing drug that when fed to mosquitoes, causes their bodies to convert an essential vitamin into another compound, in essence starving the parasite of a nutrient it needs to survive. While research remains ongoing, the scientists envision the drug being administered to mosquitoes via bait stations placed in areas with high malaria prevalence and used as part of a multipronged approach—alongside antimalarials, insecticides, vaccines, and other interventions—to reduce the global burden of this deadly disease.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Georgina Goodwin